SIRP-α/β Antibody (148): sc-53605

SIRP-α/β Antibody (148) is a mouse monoclonal IgG1 kappa light chain antibody that detects SIRP-α and SIRP-β proteins of human origin by western blotting (WB), immunoprecipitation (IP), and flow cytometry (FCM). Anti-SIRP-α/β antibody (148) targets signal-regulatory proteins, which are crucial transmembrane glycoproteins involved in the regulation of immune responses. Signal-regulatory proteins play a significant role in modulating immune cell activity by interacting with receptor tyrosine kinases and influencing downstream signaling pathways. SIRP-α contains an extracellular domain with three immunoglobulin-like structures and a cytoplasmic region rich in tyrosine phosphorylation sites, which are essential for cellular signaling function. SIRP-α phosphorylation allows binding to SH-PTP2, a protein-tyrosine phosphatase, thereby negatively regulating cellular responses to growth factors and oncogenes. This regulatory mechanism maintains cellular homeostasis and prevents uncontrolled cell proliferation, which can lead to tumorigenesis. SIRP-β1, while sharing significant sequence homology with SIRP-α, lacks the cytoplasmic domain, indicating a divergence in functional roles. The SIRP family, including SIRP-γ, which is predominantly expressed on T cells and some B cells, highlights the complexity of immune regulation and importance in maintaining immune balance.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

SIRP-α/β Antibody (148) References:

1. Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells.  |  Seiffert, M., et al. 2001. Blood. 97: 2741-9. PMID: 11313266
2. Positive regulation of phagocytosis by SIRPbeta and its signaling mechanism in macrophages.  |  Hayashi, A., et al. 2004. J Biol Chem. 279: 29450-60. PMID: 15123631
3. Surfactant protein D (Sp-D) binds to membrane-proximal domain (D3) of signal regulatory protein α (SIRPα), a site distant from binding domain of CD47, while also binding to analogous region on signal regulatory protein β (SIRPβ).  |  Fournier, B., et al. 2012. J Biol Chem. 287: 19386-98. PMID: 22511785
4. Cancer Therapy Targeting CD47/SIRPα.  |  Dizman, N. and Buchbinder, EI. 2021. Cancers (Basel). 13: PMID: 34944850
5. Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma.  |  Lu, Q., et al. 2024. Cancer Lett. 585: 216660. PMID: 38266806
6. Biomimetic Nano-Degrader Based CD47-SIRPα Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair.  |  Gao, J., et al. 2024. Adv Sci (Weinh). 11: e2306388. PMID: 38477522
7. Podocyte SIRPα reduction aggravates lupus nephritis via promoting T cell inflammatory responses.  |  Qian, B., et al. 2024. Cell Rep. 43: 114249. PMID: 38758648
8. Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells.  |  Stefanidis, E., et al. 2024. J Clin Invest. 134: PMID: 38828721
9. SIRPα engagement regulates ILC2 effector function and alleviates airway hyperreactivity via modulating energy metabolism.  |  Sakano, Y., et al. 2024. Cell Mol Immunol. 21: 1158-1174. PMID: 39160226
10. Silencing of SIRPα enhances the antitumor efficacy of CAR-M in solid tumors.  |  Zhang, H., et al. 2024. Cell Mol Immunol. 21: 1335-1349. PMID: 39379603

The preferred SIRP-α antibody is SIRP-α Antibody (SE7C2): sc-23863.